Immix Biopharma

Immix Biopharma advances NEXICART-2 study for CAR-T NXC-201, targeting relapsed/refractory AL Amyloidosis. NXC-201 shows a 92% response rate in ex-US studies, with no neurotoxicity and short cytokine release syndrome. The U.S. trial aims to evaluate safety and efficacy, building on positive data from NEXICART-1.

Immix Biopharma advances NEXICART-2 study for NXC-201, a one-time CAR-T therapy for relapsed/refractory AL Amyloidosis, showing promise with complete responses. The study, involving doses up to 450 million CAR+T cells, aims to provide a new treatment option for approximately 33,000 U.S. patients affected by this plasma cell disorder.

Cardiology gene therapy and cell therapy progress includes Rocket Pharmaceuticals completing enrollment for Danon disease gene therapy RP-A501, LX2006 improving Friedreich Ataxia cardiomyopathy biomarkers, Nexcella dosing first patient in light chain amyloidosis CAR-T trial, Verve Therapeutics starting phase 1b trial for VERVE-102, and Sardocor receiving fast track designation for heart failure gene therapy SRD-001.

Dr. Raymond Comenzo, an AL Amyloidosis expert, joined Immix Biopharma's Nexcella Scientific Advisory Board. Recognized for his work on the Andromeda trial and consensus guidelines for AL Amyloidosis, he will contribute to advancing CAR-T NXC-201 therapy for relapsed/refractory AL Amyloidosis.

Various researchers report financial relationships with pharmaceutical companies, including Deciphera, during and outside the conduct of the study.

Immix Biopharma adds Cleveland Clinic, UC Davis, and Sutter Health to its U.S. AL Amyloidosis trial, NEXICART-2, expanding patient access to CAR-T NXC-201. MSKCC remains the lead site. Initial ex-U.S. trial data showed a 92% overall response rate.